Clinical Trial: Complement C5 mAb in the Treatment of Anti-GBM Disease
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: Autoimmune Diseases
Study Type: INTERVENTIONAL
Official Title: A Single Center, Open-label, Single Arm Phase II Trial of the Efficacy and Safety of Complement C5 Monoclonal Antibody in the Treatment of Anti-glomerular Basement Membrane Disease
Brief Summary:
Anti-GBM disease is the most severe form of glomerulonephritis.Despite of the standard treatment including plasmapheresis and immunosuppressant, 70% of the patients still go into end-stage kidney disease.Complement has been shown to participate in the pathogenesis of anti-GBM disease.This study aims to the investigate the therapeutic effects and safety of C5 monoclonal antibody in the treatment of anti-GBM disease.
Read more